Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer

Freitas, Ana Julia Aguiar de; Causin, Rhafaela Lima; Varuzza, Muriele Bertagna; Calfa, Stéphanie; Filho, Cassio Murilo Trovo Hidalgo; Komoto, Tatiana Takahasi; Souza, Cristiano de Pádua; Marques, Márcia Maria Chiquitelli

doi:10.3390/ijms23179952

Cited by 54 publications

(27 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All cellular organisms secrete exosomes. Exosomes are extensively distributed and exist in many body fluids, such as plasma, urine, saliva, and cerebrospinal fluid [ 10 , 22 ].…”

Section: Exosomes: a Means Of Intercellular Communicationmentioning

confidence: 99%

Exosomes and circular RNAs: promising partners in hepatocellular carcinoma from bench to bedside

Xue

Jiang

et al. 2023

Discov Onc

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is characterized by high morbidity and mortality, and a low 5-year survival rate. Exploring the potential molecular mechanisms, finding diagnostic biomarkers with high sensitivity and specificity, and determining new therapeutic targets for HCC are urgently needed. Circular RNAs (circRNAs) have been found to play a key role in the occurrence and development of HCC, while exosomes play an important role in intercellular communication; thus, the combination of circRNAs and exosomes may have inestimable potential in early diagnosis and curative therapy. Previous studies have shown that exosomes can transfer circRNAs from normal or abnormal cells to surrounding or distant cells; thereafter, circRNAs influence target cells. This review summarizes the recent progress regarding the roles of exosomal circRNAs in the diagnosis, prognosis, occurrence and development and immune checkpoint inhibitor and tyrosine kinase inhibitor resistance of HCC to provide inspiration for further research.

show abstract

“…All cellular organisms secrete exosomes. Exosomes are extensively distributed and exist in many body fluids, such as plasma, urine, saliva, and cerebrospinal fluid [ 10 , 22 ].…”

Section: Exosomes: a Means Of Intercellular Communicationmentioning

confidence: 99%

Exosomes and circular RNAs: promising partners in hepatocellular carcinoma from bench to bedside

Xue

Jiang

et al. 2023

Discov Onc

View full text Add to dashboard Cite

show abstract

“…Multiple studies have been conducted to assess the metastatic potential of CTCs using membranous detection of epithelial and mesenchymal 14 Aliya et al, 100 Gawad et al, 101 Tang et al, 102 Wei et al, 97 Wakai et al 20 Khan et al, 104 Slatko et al, 114 Court et al, 115 Gasch et al Castro-Giner and Aceto, 94 McDonald et al, 121 Bai et al, 122 Watanabe et al, 123 Freitas et al 124 Whole-exome sequencing Gawad et al, 101 Wakai et al, 103 McDonald et al, 121 Xie et al, 125 Lohr et al, 126 Manier et al, 127 Szczerba et al 14 Lei et al, 119 Li and Wang, 129 Mustachio and Roszik 130 (Continued)…”

Section: Immunophenotypic Characterization Of Ctcs and Ctc Clustersmentioning

confidence: 99%

Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA

Yaghoubi Naei,

Bordhan,

Mirakhorli

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Over the past decade, the detection and analysis of liquid biopsy biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced significantly. They have received recognition for their clinical usefulness in detecting cancer at an early stage, monitoring disease, and evaluating treatment response. The emergence of liquid biopsy has been a helpful development, as it offers a minimally invasive, rapid, real-time monitoring, and possible alternative to traditional tissue biopsies. In resource-limited settings, the ideal platform for liquid biopsy should not only extract more CTCs or ctDNA from a minimal sample volume but also accurately represent the molecular heterogeneity of the patient’s disease. This review covers novel strategies and advancements in CTC and ctDNA-based liquid biopsy platforms, including microfluidic applications and comprehensive analysis of molecular complexity. We discuss these systems’ operational principles and performance efficiencies, as well as future opportunities and challenges for their implementation in clinical settings. In addition, we emphasize the importance of integrated platforms that incorporate machine learning and artificial intelligence in accurate liquid biopsy detection systems, which can greatly improve cancer management and enable precision diagnostics.

show abstract

“…Tumour tissues are considered the gold standard biospecimens to carry out molecular analyses in breast cancer. 79 However, there are certain conditions where their intrinsic limitations hinder appropriate molecular profiling. 80 Of note, analyses conducted on tissue samples portray tumours' state at a specific point of the disease course without being able to capture intra-tumoural heterogeneity.…”

Section: Expanding the Molecular Profilingmentioning

confidence: 99%

“…Tumour tissues are considered the gold standard biospecimens to carry out molecular analyses in breast cancer 79 . However, there are certain conditions where their intrinsic limitations hinder appropriate molecular profiling 80 .…”

Section: Integration Of Tissue and Ctdna Testingmentioning

confidence: 99%

Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing

Ranghiero,

Frascarelli,

Cursano

et al. 2023

Cytopathology

View full text Add to dashboard Cite

Breast cancer biomarker profiling predominantly relies on tissue testing (surgical and/or biopsy samples). However, the field of liquid biopsy, particularly the analysis of circulating tumour DNA (ctDNA), has witnessed remarkable progress and continues to evolve rapidly. The incorporation of ctDNA‐based testing into clinical practice is creating new opportunities for patients with metastatic breast cancer (MBC). ctDNA offers advantages over conventional tissue analyses, as it reflects tumour heterogeneity and enables multiple serial biopsies in a minimally invasive manner. Thus, it serves as a valuable complement to standard tumour tissues and, in certain instances, may even present a potential alternative approach. In the context of MBC, ctDNA testing proves highly informative in the detection of disease progression, monitoring treatment response, assessing actionable biomarkers, and identifying mechanisms of resistance. Nevertheless, ctDNA does exhibit inherent limitations, including its generally low abundance, necessitating timely blood samplings and rigorous management of the pre‐analytical phase. The development of highly sensitive assays and robust bioinformatic tools has paved the way for reliable ctDNA analyses. The time has now come to establish how ctDNA and tissue analyses can be effectively integrated into the diagnostic workflow of MBC to provide patients with the most comprehensive and accurate profiling. In this manuscript, we comprehensively analyse the current methodologies employed in ctDNA analysis and explore the potential benefits arising from the integration of tissue and ctDNA testing for patients diagnosed with MBC.

show abstract

Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer

Cited by 54 publications

References 136 publications

Exosomes and circular RNAs: promising partners in hepatocellular carcinoma from bench to bedside

Exosomes and circular RNAs: promising partners in hepatocellular carcinoma from bench to bedside

Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA

Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing

Contact Info

Product

Resources

About